Target intelligence / Profile preview

Gastric and intestinal mucosal surfaces (GI mucosa)

Target
GI mucosa
Molecular classification
Other
01

Overview

The gastric and intestinal mucosal surfaces constitute the innermost lining of the gastrointestinal tract, acting as a vital barrier between the lumen and the systemic circulation (NIH: Gastrointestinal Mucosal Barrier, 2013). This multi-layered structure consists of an epithelial cell layer, a protective mucus coating, and the underlying lamina propria, which houses a significant portion of the body's immune system. Its primary biological roles include the selective absorption of nutrients, the secretion of digestive juices, and the prevention of pathogen entry (StatPearls: Physiology, Gastrointestinal, 2023). Pathological conditions such as peptic ulcers, gastritis, and inflammatory bowel disease involve the breakdown or inflammation of these surfaces. Pharmacological strategies often focus on enhancing mucosal defense mechanisms or reducing aggressive factors to promote healing and maintain the integrity of the gastrointestinal barrier (PubChem: Sucralfate, 2024). While not a single molecular target, these surfaces are the site of action for various cytoprotective and anti-inflammatory agents.

Other names
Gastrointestinal mucosaGastric mucosaIntestinal mucosaGut liningDigestive tract liningMucosal barrier
02

Mechanism of action

Drugs interacting with these surfaces typically function by providing a physical protective coating, stimulating the production of protective mucus and bicarbonate, or reducing the secretion of damaging agents like gastric acid to allow for tissue repair (StatPearls: Physiology, Gastrointestinal, 2023).

03

Biological functions

Barrier functionNutrient absorptionSecretionImmune responseHomeostasis
04

Disease associations

Peptic ulcer diseaseGastritisInflammatory bowel diseaseCeliac diseaseGastroesophageal reflux disease (GERD)Infection
05

Safety considerations

Potential for systemic toxicity from localized treatmentsMasking of symptoms of underlying malignancyAlteration of the gut microbiomeMalabsorption of nutrients
06

Interacting drugs

Sucralfate

6 more in the full profile.

07

Biomarkers

Fecal calprotectinFecal lactoferrinEndoscopic mucosal healingC-reactive protein (CRP)

Beyond the preview

Go deeper on Gastric and intestinal mucosal surfaces (GI mucosa).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gastric and intestinal mucosal surfaces (GI mucosa).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call